Letters
POPADAD trial
Author’s reply
BMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2582 (Published 19 November 2008) Cite this as: BMJ 2008;337:a2582
- Jill Belch, professor of vascular medicine1
- 1Institute of Cardiovascular Research, University of Dundee, Ninewells Hospital, Dundee DD1 9SY
- j.j.f.belch{at}dundee.ac.uk
We support Elwood’s suggestion to include our study in a meta-analysis of all aspirin primary prevention studies. We believe this may already be in draft form, but such an analysis, albeit without POPADAD, yielded negative results.1
We agree that the event rate …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.